Phathom Pharmaceuticals (PHAT) Gross Margin (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Gross Margin data on file, last reported at 79.42% in Q1 2026.

• Gross Margin for Q1 2026 came in at 79.42%, down 752.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 84.93% (down 130.0% YoY), and the FY2025 annual result was 87.09%, up 152.0% from the prior year.
• Gross Margin retreated to 79.42% in Q1 2026 per PHAT's latest filing, from 86.72% in the prior quarter.
• Over five years, Gross Margin peaked at 87.5% in Q3 2025 and troughed at 75.51% in Q4 2023.
• A 4-year average of 83.5% and a median of 86.16% in 2024 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2024 and 2026: Gross Margin jumped 1163 bps in 2024, then tumbled 752 bps in 2026.
• A 4-year view of Gross Margin shows it stood at 75.51% in 2023, then climbed by 15 bps to 87.14% in 2024, then declined by 0 bps to 86.72% in 2025, then retreated by 8 bps to 79.42% in 2026.
• Business Quant data shows PHAT's Gross Margin at 79.42% in Q1 2026, 86.72% in Q4 2025, and 87.5% in Q3 2025.